Patents by Inventor Florence SONNEVILLE

Florence SONNEVILLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination treatment for cystic fibrosis
    Patent number: 11261445
    Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 1, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Olivier Tabary, Florence Sonneville, Harriet Corvol
  • Methods and pharmaceutical compositions for the treatment of cystic fibrosis
    Patent number: 11130950
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 28, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITÉ
    Inventors: Olivier Tabary, Florence Sonneville
  • COMBINATION TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20210189390
    Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Inventors: Olivier TABARY, Florence SONNEVILLE, Harriet CORVOL
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20200040332
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.
    Type: Application
    Filed: July 1, 2016
    Publication date: February 6, 2020
    Inventors: Olivier TABARY, Florence SONNEVILLE